Multiple myeloma (MM) remains a complex and heterogeneous hematologic malignancy with evolving therapeutic challenges. In recent years, immunotherapy has ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and ...

In a new study published in Cancer Immunology Research, scientists at the Icahn School of Medicine at Mount Sinai have ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Current approved CAR T-cell therapy treatments rely on an ex vivo route, in which a patient’s T cells are removed, genetically engineered to target antigens, and put back into the patient.

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Fragile X disorders include two distinct conditions: fragile X syndrome (the most common single-gene cause of developmental ...